ReviewMicroorganisms2025
Candidiasis: Insights into Virulence Factors, Complement Evasion and Antifungal Drug Resistance.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Review
- Therapeutic potential of traditional Chinese medicine-derived formulations and extracts inJournal of pharmaceutical analysis · 2026Review
- New Acylglucoses fromPlants (Basel, Switzerland) · 2026Article
- Subtractive proteomics-assisted putative drug target and inhibitor identification: a study based on six Candida species.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- Candida-associated immune and metabolic rewiring in chronic obstructive pulmonary disease.BMC pulmonary medicine · 2026Article
- A simplified MALDI-TOF MS method for rapid fluconazole susceptibility testing inJournal of medical microbiology · 2026Article
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris.NPJ vaccines · 2026Article
- Article
- Microecological Interventions against Antibiotic-Induced Dysbiosis and Related Resistome Expansion.Journal of microbiology and biotechnology · 2026Review
- Article
- Candidemia in Southern Poland (2017-2022): Multicenter Analysis of Species Distribution and Antifungal Susceptibility.Journal of fungi (Basel, Switzerland) · 2026Article
- Complement C9 deficiency as a novel risk factor for invasive Candida esophagitis in children: a single case in-depth analysis.BMC pediatrics · 2026Article
- Avian Candidiasis: A Comprehensive Review of Pathogenesis, Diagnosis, and Control.Veterinary sciences · 2026Review
- Antifungal Effects of Pterostilbene onJournal of fungi (Basel, Switzerland) · 2025Article
- An optimized protocol forbioRxiv : the preprint server for biology · 2025Article
- Harnessing Probiotics to Combat Candidiasis: Mechanisms, Evidence, and Future Directions.Journal of fungi (Basel, Switzerland) · 2025Review
- The trio of Candida albicans, immune cells, and cancer progression: a complex interplay driving tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- Discrimination of Clinical and Food-DerivedPathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal infections constitute a substantial global health burden, with invasive candidiasis representing approximately 70% of reported cases worldwide. The emergence of antifungal resistance among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.